JBC PeproTech; Our Business is Cytokines!

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Casella, S. J.
Right arrow Articles by Van Wyk, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Casella, S. J.
Right arrow Articles by Van Wyk, J. J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J. Biol. Chem., Vol. 261, Issue 20, 9268-9273, 07, 1986

Insulin-like growth factor II binding to the type I somatomedin receptor. Evidence for two high affinity binding sites

SJ Casella, VK Han, AJ D'Ercole, ME Svoboda and JJ Van Wyk

We have previously shown that the antireceptor antibody alpha IR-3 inhibits binding of 125I-somatomedin-C/insulin-like growth factor I (Sm- C/IGF-I) to the 130-kDa alpha subunit of the type I receptor in human placental membranes, but does not block 125I-insulin-like growth factor II (IGF-II) binding to a similar 130-kDa complex in these membranes. To determine whether the 130-kDa 125I-IGF-II binding complex represents a homologous receptor or whether 125I-IGF-II binds to the type I receptor at a site that is not blocked by alpha IR-3, type I receptors were purified by affinity chromatography on Sepharose linked alpha IR-3. The purified receptors bound both 125I-Sm-C/IGF-I and 125I-IGF-II avidly (KD = 2.0 X 10(-10) M and 3.0 X 10(-10) M, respectively). The maximal inhibition of 125I-Sm-C/IGF-I binding by the antibody, however, was 62% while only 15% of 125I-IGF-II binding was inhibited by alpha IR-3. In the presence of 500 nM alpha IR-3, Sm-C/IGF-I bound with lower affinity (KD = 6.5 X 10(-10) M) than IGF-II (KD = 4.5 X 10(-10) M) and IGF-II was the more potent inhibitor of 125I-Sm-C/IGF-I binding. These findings suggest that the type I receptor contains two different binding sites. The site designated IA has highest affinity for Sm-C/IGF- I and is blocked by alpha IR-3. Site IB has higher affinity for IGF-II than for Sm-C/IGF-I and is not blocked by alpha IR-3.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. K. Larsen, C.-C. Chen, and P. M. Best
Disruption of growth hormone secretion alters Ca2+ current density and expression of Ca2+ channel and insulin-like growth factor genes in rat atria
Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H829 - H838.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. Burtrum, Z. Zhu, D. Lu, D. M. Anderson, M. Prewett, D. S. Pereira, R. Bassi, R. Abdullah, A. T. Hooper, H. Koo, et al.
A Fully Human Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor Blocks Ligand-Dependent Signaling and Inhibits Human Tumor Growth in Vivo
Cancer Res., December 15, 2003; 63(24): 8912 - 8921.
[Abstract] [Full Text] [PDF]


Home page
Arch SurgHome page
M. L. Gimbel, D. Chelius, T. K. Hunt, and E. M. Spencer
A Novel Approach to Reducing Postoperative Intraperitoneal Adhesions Through the Inhibition of Insulinlike Growth Factor I Activity
Arch Surg, March 1, 2001; 136(3): 311 - 317.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
N. Miyakoshi, C. Richman, X. Qin, D. J. Baylink, and S. Mohan
Effects of Recombinant Insulin-Like Growth Factor-Binding Protein-4 on Bone Formation Parameters in Mice
Endocrinology, December 1, 1999; 140(12): 5719 - 5728.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
Z.-D. Xu, L. Oey, S. Mohan, M. H. Kawachi, N.-S. Lee, J. J. Rossi, and Y. Fujita-Yamaguchi
Hammerhead Ribozyme-Mediated Cleavage of the Human Insulin-Like Growth Factor-II Ribonucleic Acid in Vitro and in Prostate Cancer Cells
Endocrinology, May 1, 1999; 140(5): 2134 - 2144.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
Y. Yamanaka, E. M. Wilson, R. G. Rosenfeld, and Y. Oh
Inhibition of Insulin Receptor Activation by Insulin-like Growth Factor Binding Proteins
J. Biol. Chem., December 5, 1997; 272(49): 30729 - 30734.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. Hashimoto, H. Fujiwara, N. Higashihashi, T. Enjoh-Kimura, H. Terasawa, Y. Fujita-Yamaguchi, F. Inagaki, J. F. Perdue, and K.-i. Sakano
N-terminal Deletion Mutants of Insulin-like Growth Factor-II (IGF-II) Show Thr[IMAGE] and Leu[IMAGE] Important for Binding to Insulin and IGF-I Receptors and Leu[IMAGE] Critical for All IGF-II Functions
J. Biol. Chem., July 28, 1995; 270(30): 18013 - 18018.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 1986 by the American Society for Biochemistry and Molecular Biology.